

## NZX/ASX Announcement

14 December 2023

### TruScreen Wins Top Prize in Poland's international Mother and Child Institute (MCI) Start Up Challenge

#### Highlights of the prizes:

- Main sponsor's prize: MCI and OVHcloud grand prize: one-year support for implementation of technology in Poland and 100,000 euros of icloud storage
- Sponsor TIKA company; prize: free access to the online course "Successful Market Entry - the USA."
- GE HealthCare; prize: mentoring support (12h).

TruScreen Group Limited (NZX/ASX:TRU) is pleased to announce winning the Polish Mother and Child Institute (MCI) Start Up Challenge as one of top 2 winners among 51 international submissions of advanced, innovative technologies, focused on artificial intelligence and data acquisition in healthcare.

This 7-month long competition, was sponsored by 17 international organisations, including Medical Research Agency and Poland's Ministry of Health, IQvia, GE Healthcare, Astra Zeneca and European Union, among others. This significant award recognition will accelerate TruScreen technology implementation in a leading public hospital network in Poland. In their acknowledgement, the Selection Committee, consisting of MCI, and several top Polish healthcare organisations recognised the value of TruScreen, accelerating cervical cancer screening at lower public healthcare costs and more patient-focused, innovative approach.

The prizes will enable TruScreen to accelerate its data acquisition and enable highly regarded mentoring access from one of the global healthcare innovators, GE Healthcare.

CEO, Dr Beata Edling commented:

*"Our sincere thanks to the MCSC hospitals, GE Healthcare, Tika, OVHcloud, and organisers of the international competition, for enabling acceleration of the implementation of TruScreen in Poland and Eastern Europe. We thank you for recognising TruScreen technology as an excellent screening method for cervical cancer, fit for 21st century healthcare. TruScreen is world-class technology made simple enabling women access to a painless, fast, and very reliable cervical screening. We are delighted with the recognition and look forward to collaborating on reducing cervical cancer in Poland."*

This announcement has been approved by the Board.

**Ends**



truscreen  
a world without  
cervical cancer

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Dr Beata Edling  
Chief Executive Officer  
[beataedling@truscreen.com](mailto:beataedling@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

### About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra<sup>®</sup>, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In financial year 2023 alone, over 140000\* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"<sup>®</sup>.

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/).

*\*Based on Single Use Sensor sales.*

For personal use only



truscreen  
a world without  
cervical cancer

Glossary:

**Pap smear** (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. <https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test>

**LBC** (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test <https://www.cancer.net/cancer-types/cervical-cancer/diagnosis>

**HPV (human papilloma virus) test** is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. <https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention>

**Sensitivity and specificity** mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, [conditioned](#) on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative ([Sensitivity and specificity – Wikipedia](#)).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: [National Cervical Screening Programme | National Screening Unit \(nsu.govt.nz\)](#)

Australia: [Cervical cancer | Causes, Symptoms & Treatments | Cancer Council](#)